Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Siemens Healthineers and Cleveland Clinic Announce 10-Year Strategic Partnership

Fineline Cube Aug 4, 2026
Company Deals

Apeloa Pharmaceutical and METiS Therapeutics Announce Strategic CDMO Partnership

Fineline Cube Aug 4, 2026
Company Deals

ELI Radiopharma and United Imaging Research Institute Forge Strategic Alliance to Advance Radiopharmaceutical Innovation

Fineline Cube Aug 4, 2026
Company Deals

Qyuns Therapeutics’ Partner Caldera to Merge with Synlogic in $278M Backed Deal, Advancing TL1A/IL-23p19 Bispecific Antibody for Inflammatory Bowel Disease

Fineline Cube Jul 30, 2026
Company Deals

China Resources Pharmaceutical to Acquire Lier Chemical for $795M in Strategic Move into Agrochemical Sector

Fineline Cube Jul 30, 2026
Drug Medical Device Policy / Regulatory

NMPA Proposes Framework for Synchronized Development of Anti-Tumor Drugs and Companion Diagnostics

Fineline Cube Aug 4, 2026
Company Drug

Zai Lab’s Zocilurtatug Pelitecan Receives FDA Orphan Drug Designation for Neuroendocrine Carcinoma

Fineline Cube Aug 4, 2026
Drug

FDA Grants Biologics License to Ezplaz Freeze-Dried Plasma, First FDP Approved in United States

Fineline Cube Aug 4, 2026
Company Deals

InxMed Partners with GeneQuantum Healthcare to Develop Innovative ADCs

Fineline Cube Aug 2, 2023

China-based firm InxMed (Nanjing) Co., Ltd has announced a strategic partnership with compatriot firm GeneQuantum...

Company Deals

Sansure Biotech Partners with Indonesian Firm for Localized Molecular Diagnostic Production

Fineline Cube Aug 2, 2023

China-based molecular diagnostics specialist Sansure Biotech Inc. (SHA: 688289) has announced a strategic partnership with...

Company R&D

Sinopharm Partners with Harbin Institute of Technology to Boost Biomedical Industry Innovation

Fineline Cube Aug 2, 2023

China National Pharmaceutical Group Corporation (Sinopharm, HKG: 1099) has announced a strategic partnership with Harbin...

Company Deals

NK Celltech and RongCan Biotech Partner to Advance mRNA NK Cell Therapy and LNP Delivery System

Fineline Cube Aug 2, 2023

Shanghai-based NK Celltech and RongCan Biotech have entered into a partnership agreement to establish a...

Company Drug

Abbisko Therapeutics Initiates Phase II Clinical Trial for Pimicotinib in Tendon Sheath Giant Cell Tumor

Fineline Cube Aug 2, 2023

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced the dosing of the first...

Company Deals

CASI Pharmaceuticals Enters Assignment Agreement with Mundipharma for Folotyn Commercialization in China

Fineline Cube Aug 2, 2023

US-based CASI Pharmaceuticals Inc., (NASDAQ: CASI) has announced the execution of an assignment agreement with...

Company Drug

Astellas Pharma’s Zolbetuximab BLA Accepted by China’s CDE for Gastric Cancer Treatment

Fineline Cube Aug 2, 2023

Japan-based Astellas Pharma Inc. (TYO: 4503) has announced that the Center for Drug Evaluation (CDE)...

Company Deals

Shanghai Junshi Biosciences Partners with Zein Biotechnology for PCSK9 mAb Commercialization in China

Fineline Cube Aug 2, 2023

China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced a partnership with...

Company

MSD’s Q2 2023 Earnings: Keytruda and Gardasil Drive Growth Amid COVID-19 Sales Decline

Fineline Cube Aug 2, 2023

US-based major Merck, Sharp & Dohme Inc., (MSD; NYSE: MRK) has released its financial results...

Company

GluBio Pharmaceutical Secures $22 Million in A+ Round Financing to Advance Protein Degradation Drugs

Fineline Cube Aug 1, 2023

GluBio Pharmaceutical Co., Ltd., an emerging player in targeted protein degradation drug development, has announced...

Company Drug

GSK’s Jemperli Receives FDA Approval for First-Line Treatment of Advanced Endometrial Cancer

Fineline Cube Aug 1, 2023

GSK plc (NYSE: GSK), a major UK pharmaceutical company, has announced that the US Food...

Company Drug

Viatris Inc. Secures FDA Nod for Generic Symbicort Equivalent, Breyna

Fineline Cube Aug 1, 2023

US-based Viatris Inc., (NASDAQ: VTRS) has announced that the US Food and Drug Administration (FDA)...

Company Deals

Mindray Bio-Medical Electronics to Acquire Majority Stake in DiaSys Diagnostic Systems

Fineline Cube Aug 1, 2023

Shenzhen Mindray Bio-Medical Electronics Co., Ltd (SHE: 300760), a leading medical device company based in...

Company Deals

EnChannel Secures RMB 200 Million in Series A Funding to Advance Electrophysiology Solutions

Fineline Cube Aug 1, 2023

EnChannel Medical, a Guangzhou-based electrophysiology platform company, has reportedly secured RMB 200 million (USD 28...

Company Deals

Sinovation Secures Over RMB 100 Million in Series D+ Financing for Neurosurgery Innovations

Fineline Cube Aug 1, 2023

Beijing-based Sinovation (Beijing) Medical Technology Co., Ltd., a leader in neurosurgery diagnosis, minimally invasive procedure...

Company Medical Device

Peijia Medical Commences Clinical Study for Taurus Trio TAVR System with First Patient Enrollment

Fineline Cube Aug 1, 2023

Peijia Medical Ltd (HKG: 9996) has announced the enrollment of the first patient in a...

Company Drug

RemeGen’s Novel Bispecific Antibody RC148 Receives Clinical Trial Approval

Fineline Cube Aug 1, 2023

China-based RemeGen Ltd (SHA: 688331, HKG: 9995) has announced that it has received clinical trial...

Company R&D

Hainan Boao Lecheng Partners with BeiGene to Boost Medical Tourism and Biotech Innovation

Fineline Cube Aug 1, 2023

The Hainan Boao Lecheng International Medical Tourism Pilot Zone has entered into a partnership with...

Company Drug

Jiangsu Hengrui’s Camrelizumab and Apatinib Combo Accepted for FDA Review for HCC Treatment

Fineline Cube Aug 1, 2023

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that the US Food and Drug...

Company Drug

Jacobio Pharma’s Glecirasib Enters Breakthrough Therapy Review for Pancreatic Cancer Treatment

Fineline Cube Aug 1, 2023

China-based Jacobio Pharma (HKG: 1167) has announced that its novel KRAS G12C inhibitor, glecirasib, has...

Posts pagination

1 … 531 532 533 … 703

Recent updates

  • Zai Lab’s Zocilurtatug Pelitecan Receives FDA Orphan Drug Designation for Neuroendocrine Carcinoma
  • FDA Grants Biologics License to Ezplaz Freeze-Dried Plasma, First FDP Approved in United States
  • Novartis’ Pluvicto Receives FDA Approval for Metastatic Hormone-Sensitive Prostate Cancer
  • HutchMed Reports H1 2026 Results with Strong Oncology Growth Despite Overall Revenue Decline
  • Siemens Healthineers and Cleveland Clinic Announce 10-Year Strategic Partnership
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Zai Lab’s Zocilurtatug Pelitecan Receives FDA Orphan Drug Designation for Neuroendocrine Carcinoma

Drug

FDA Grants Biologics License to Ezplaz Freeze-Dried Plasma, First FDP Approved in United States

Company Drug

Novartis’ Pluvicto Receives FDA Approval for Metastatic Hormone-Sensitive Prostate Cancer

Company

HutchMed Reports H1 2026 Results with Strong Oncology Growth Despite Overall Revenue Decline

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.